Novo Nordisk to buy Prothena’s heart drug in deal worth up to $1.2 bln
July 12 (Reuters) – Danish drugmaker Novo Nordisk (NOVOb.CO) will acquire U.S. drug developer Prothena Corp’s (PRTA.O) experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday. The acquisition is in line with Novo’s strategy to diversify its core insulin portfolio that has been facing tough competition, prompting it […]
A $9 million boss? UniCredit investors to decide how much Orcel is worth
MILAN (Reuters) – Investors are due to approve Andrea Orcel’s appointment as chief executive of UniCredit on Thursday, but the issue that scuppered his first attempt to run a major bank is overshadowing his second: pay.
